Abstract
BackgroundThe use of Rituximab in vasculitis, systemic lupus erythematosus and some other systemic autoimmune diseases reduces activity of process. It also demonstrated the low rate of disease progression. The standard...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
